Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.
【저자키워드】 SARS-CoV-2, pediatric, children, eculizumab, complement, acute respiratory distress syndrome (ARDS), COVID - 19, 【초록키워드】 COVID-19, convalescent plasma, ARDS, SARS-CoV, lung, animal model, Acute kidney injury, acute lung injury, Deterioration, AKI, Critically ill, Asymptomatic, Lung function, disease, Immune-mediated, acute respiratory distress, inflammatory pathways, syndrome, lung tissue, mild illness, MOST, died, supported, treated, children with COVID-19, patients with COVID-19, with COVID-19, 【제목키워드】 COVID-19, inhibition, respiratory,